Treatment of Papillary Thyroid Carcinoma >4 cm, with Extrathyroidal Extension, or Metastatic Disease (cT3a, cT3b, cT4, cN1, or cM1)
This protocol applies to patients with papillary thyroid carcinoma who meet high-risk staging criteria — tumors larger than 4 cm, gross extrathyroidal extension, clinically apparent regional lymph node metastasis, or confirmed distant metastasis.
Clinical Scenario
The approach is indicated for papillary thyroid carcinoma >4 cm (cT3a), tumor of any size with gross extrathyroidal extension (cT3b or cT4), clinically apparent regional lymph node metastasis (cN1), or distant metastasis (cM1). These presentations require total thyroidectomy with gross removal of all primary tumor and node dissection as the foundational surgical step.
Treatment Overview
Following total thyroidectomy, management of this high-risk presentation involves radioactive iodine (⁻¹¹¹I) therapy with a carefully defined TSH preparation protocol — the complete regimen, preparation method, and dosing strategy are available in the full structured protocol below.
Full regimen details and sequencing are available via the link below.
Treatment Goals
Significant reduction in serum thyroglobulin level and/or in the size or rate of growth of structurally apparent disease.
References
DOI: 10.1177/10507256251363120
- For patients with thyroid cancer >4 cm (cT3a), cancer of any size with gross extra-thyroidal extension (cT3b or cT4), or clinically apparent metastatic disease to lymph nodes (cN1) or distant sites (cM1), the initial surgical procedure should include a total thyroidectomy with gross removal of all primary tumor and node dissection unless there are contraindications to this procedure.
- RAI adjuvant therapy is recommended routinely after total thyroidectomy for patients with ATA high-risk DTC.
- In patients with an initial diagnosis of DTC with distant metastases, RAI therapy is recommended routinely after total thyroidectomy.
- In patients with DTC in whom RAI remnant ablation or adjuvant therapy is planned, preparation with rhTSH stimulation is preferred over thyroid hormone withdrawal.
- A goal of TSH >30 mIU/L should be employed in preparation for RAI therapy or diagnostic testing.
- A meaningful response to RAI is generally a significant reduction in serum Tg level and/or the size (or rate of growth) of structurally apparent disease.
View source ↗